ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
After market 01:00:00 | |||
| 807.4 USD | -0.13% |
|
806.5 | -0.12% |
| 05-24 | Health Care Down on Rotation Out of Sector - Health Care Roundup | DJ |
| 05-24 | News Highlights : Top Company News of the Day - Friday at 5 PM ET | DJ |
| Sales 2024 * | 43B 3,376B | Sales 2025 * | 52.61B 4,131B | Capitalization | 727B 57,083B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.93B 937B | Net income 2025 * | 16.55B 1,300B | EV / Sales 2024 * | 17.4 x |
| Net Debt 2024 * | 19.98B 1,569B | Net Debt 2025 * | 15.29B 1,200B | EV / Sales 2025 * | 14.1 x |
| P/E ratio 2024 * |
60.4
x | P/E ratio 2025 * |
43.5
x | Employees | 43,000 |
| Yield 2024 * |
0.64% | Yield 2025 * |
0.74% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | -0.12% | ||
| 1 week | +4.86% | ||
| Current month | +3.37% | ||
| 1 month | +10.27% | ||
| 3 months | +4.92% | ||
| 6 months | +34.33% | ||
| Current year | +38.51% |
1 week
766.12
820.61
1 month
721.00820.61
Current year
579.05820.61
1 year
422.06820.61
3 years
195.50820.61
5 years
101.36820.61
10 years
58.50820.61
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 31/12/95 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 31/12/00 |
Ruth Gimeno
PSD | President | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 24/01/21 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 31/03/09 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 31/12/04 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.49% | 17 M€ | +7.15% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/05/24 | 807.4 | -0.13% | 1,778,120 |
| 23/05/24 | 808.4 | +0.69% | 3,025,781 |
| 22/05/24 | 802.9 | -0.03% | 1,767,519 |
| 21/05/24 | 803.2 | +2.55% | 4,334,499 |
| 20/05/24 | 783.2 | +1.71% | 2,188,818 |
Delayed Quote Nyse, May 24, 2024 at 09:00 pm
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
807.4
USD
Average target price
850.8
USD
Spread / Average Target
+5.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +38.51% | 727B | |
| +33.05% | 599B | |
| -6.23% | 354B | |
| +18.78% | 328B | |
| +1.35% | 277B | |
| +16.00% | 243B | |
| +8.09% | 205B | |
| -5.77% | 203B | |
| +6.19% | 164B | |
| +0.31% | 164B |
- Stock Market
- Equities
- LLY Stock
